These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12870566)

  • 1. Reboxetine promotes social bonding in healthy volunteers.
    Tse WS; Bond AJ
    J Psychopharmacol; 2003 Jun; 17(2):189-95. PubMed ID: 12870566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Difference in serotonergic and noradrenergic regulation of human social behaviours.
    Tse WS; Bond AJ
    Psychopharmacology (Berl); 2002 Jan; 159(2):216-21. PubMed ID: 11862352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noradrenaline might enhance assertive human social behaviours: an investigation in a flatmate relationship.
    Tse WS; Bond AJ
    Pharmacopsychiatry; 2006 Sep; 39(5):175-9. PubMed ID: 16944408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonergic intervention affects both social dominance and affiliative behaviour.
    Tse WS; Bond AJ
    Psychopharmacology (Berl); 2002 May; 161(3):324-30. PubMed ID: 12021836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of reboxetine, a noradrenaline reuptake inhibitor, on the plasma noradrenaline response to a cold pressor test in healthy volunteers.
    Kelly CB; McAree S; Cooper SJ; Stevenson M
    J Psychopharmacol; 2002 Dec; 16(4):333-6. PubMed ID: 12503832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance.
    Schroeder C; Tank J; Boschmann M; Diedrich A; Sharma AM; Biaggioni I; Luft FC; Jordan J
    Circulation; 2002 Jan; 105(3):347-53. PubMed ID: 11804991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of reboxetine on autonomic and cognitive functions in healthy volunteers.
    Siepmann M; Mück-Weymann M; Joraschky P; Kirch W
    Psychopharmacology (Berl); 2001 Sep; 157(2):202-7. PubMed ID: 11594447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local and Global Resting State Activity in the Noradrenergic and Dopaminergic Pathway Modulated by Reboxetine and Amisulpride in Healthy Subjects.
    Metzger CD; Wiegers M; Walter M; Abler B; Graf H
    Int J Neuropsychopharmacol; 2015 Jul; 19(2):. PubMed ID: 26209860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analgesic effect of the selective noradrenaline reuptake inhibitor reboxetine].
    Schüler P; Seibel K; Chevts V; Schaffler K
    Nervenarzt; 2002 Feb; 73(2):149-54. PubMed ID: 11975091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The need for new and better antidepressants: reboxetine a new option.
    Dencker SJ
    Acta Psychiatr Scand Suppl; 2000; 402():6-11. PubMed ID: 10901153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of noradrenergic activity on temporal information processing in humans.
    Rammsayer TH; Hennig J; Haag A; Lange N
    Q J Exp Psychol B; 2001 Aug; 54(3):247-58. PubMed ID: 11547514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal cortex.
    Page ME; Lucki I
    Neuropsychopharmacology; 2002 Aug; 27(2):237-47. PubMed ID: 12093597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reboxetine: the first selective noradrenaline re-uptake inhibitor.
    Kasper S; el Giamal N; Hilger E
    Expert Opin Pharmacother; 2000 May; 1(4):771-82. PubMed ID: 11249515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons.
    Szabo ST; Blier P
    Eur J Neurosci; 2001 Jun; 13(11):2077-87. PubMed ID: 11422448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.
    Poyurovsky M; Isaacs I; Fuchs C; Schneidman M; Faragian S; Weizman R; Weizman A
    Am J Psychiatry; 2003 Feb; 160(2):297-302. PubMed ID: 12562576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans.
    Hysek CM; Simmler LD; Ineichen M; Grouzmann E; Hoener MC; Brenneisen R; Huwyler J; Liechti ME
    Clin Pharmacol Ther; 2011 Aug; 90(2):246-55. PubMed ID: 21677639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of repeated treatment with reboxetine on the central alpha1-adrenergic system.
    Rogóz Z; Kolasiewicz W
    Pol J Pharmacol; 2001; 53(6):663-7. PubMed ID: 11985343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Reboxetine (Edronax)].
    Souery D; Sternon J
    Rev Med Brux; 1999 Dec; 20(6):511-6. PubMed ID: 10672775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reboxetine attenuates forced swim test-induced behavioural and neurochemical alterations in the rat.
    Connor TJ; Kelliher P; Harkin A; Kelly JP; Leonard BE
    Eur J Pharmacol; 1999 Aug; 379(2-3):125-33. PubMed ID: 10497898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic reboxetine desensitizes terminal but not somatodendritic alpha2-adrenoceptors controlling noradrenaline release in the rat dorsal hippocampus.
    Parini S; Renoldi G; Battaglia A; Invernizzi RW
    Neuropsychopharmacology; 2005 Jun; 30(6):1048-55. PubMed ID: 15668723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.